Targeting of Natural Killer Cells to Mammary Carcinoma via Naturally Occurring Tumor Cell-Bound iC3b and β-Glucan-Primed CR3 (CD11b/CD18)

Journal of Immunology

Volumn 159, Issue 2, 1997, Pages 599-605

  Vetvicka, Vaclav ^a   Thornton, Brian P ^a   Wieman, T Jeffery ^b   Ross, Gordon D ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD18 ANTIGEN; GLUCAN;

ADULT; AGED; ARTICLE; BREAST TUMOR; CARCINOMA; CELL CULTURE; CELLULAR IMMUNITY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; MIDDLE AGED; NATURAL KILLER CELL; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD18; BREAST NEOPLASMS; CARCINOMA; FEMALE; FLOW CYTOMETRY; GLUCANS; HUMANS; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; MACROPHAGE-1 ANTIGEN; MIDDLE AGED; TUMOR CELLS, CULTURED;

EID: 0031570899     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Irie, K., R. F. Irie, and D. L. Morton. 1974. Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells. Science 186:454.
2. Seegal, B. C., K. C. Hsu, J. K. Lattimer, D. V. Habif, and M. Tannenbaum. 1976. Immunoglobulins, complement and foreign antigens in human tumor cells. Int. Arch. Allergy Appl. Immunol. 52:205.
3. Niculescu, F., H. G. Rus, M. Retegan, and R. Vlaicu. 1992. Persistent complement activation on tumor cells in breast cancer. Am. J. Pathol. 140:1039.
4. Kotera, Y., J. D. Fontenot, G. Pecher, R. S. Metzgar, and O. J. Finn. 1994. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res. 54:2856.
5. Seya, T., T. Hara, M. Matsumoto, Y. Sugita, and H. Akedo. 1990. Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46). J. Exp. Med. 172:1673.
6. Niehans, G. A., D. L. Cherwitz, N. A. Staley, D. J. Knapp, and A. P. Dalmasso. 1996. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. Pathol. 149:129.
7. Gasque, P., A. Thomas, M. Fontaine, and B. P. Morgan. 1996. Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. J. Neuroimmunol. 66: 29.
8. Junnikkala, S., J. Hakulinen, and S. Meri. 1994. Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells. Eur. J. Immunol. 24:611.
9. Vetvicka, V., B. P. Thornton, and G. D. Ross. 1996. Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or NK cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J. Clin. Invest. 98:50.
10. Diamond, M. S., J. Garcia-Aguilar, J. K. Bickford, A. L. Corbi, and T. A. Springer. 1993. The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J. Cell Biol. 120:1031.
11. Thornton, B. P., V. Vetvicka, M. Pitman, R. C. Goldman, and G. D. Ross. 1996. Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol. 156:1235.
12. Diller, I. C., M. E. Fisher, and D. Gable. 1964. Effect of glucan on mouse sarcoma 37. Proc. Soc. Exp. Biol. Med. 117:107.
13. Chihara, G., Y. Maeda, J. Hamuro, T. Sasaki, and F. Fukuoka. 1969. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) Sing. Nature 222:687.
14. Mansell, P. W. A., G. Rowden, and C. Hammer. 1978. Clinical experiences with the use of glucan. In Immune Modulation and Control of Neoplasia by Adjuvant Therapy, Progress in Cancer Research and Therapy, Vol. 7. M. A. Chirigos, ed. Raven Press, New York, p. 255.
15. Nakao, I., H. Uchino, K. Orita, I. Kaido, T. Kimura, Y. Goto, T. Kondo, T. Takino, T. Taguchi, T. Nakajima, S. Fujimoto, T. Miyazaki, A. Miyoshi, A. Yachi, K. Yoshida, N. Ogawa, and H. Furue. 1983. Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer: a randomized comparative study by an envelop method. Jpn. J. Cancer Chemother. 10:1146.
16. Taguchi, T., H. Furue, T. Kimura, T. Kondo, T. Hattori, and N. Ogawa. 1983. Clinical efficacy of lentinan on neoplastic diseases. Adv. Exp. Med. Biol. 166:181.
17. Ohno, N., Y. Adachi, I. Suzuki, S. Oikawa, K. Sato, M. Ohsawa, and T. Yadomae. 1986. Antitumor activity of a β-1,3-glucan obtained from liquid cultured mycelium of Grifola frondosa. J. Pharmacobiodyn. 9:861.
18. Ohno, N., K. Kurachi, and T. Yadomae. 1987. Antitumor activity of a highly branched (1->3)-β-D-glucan, SSG, obtained from Sclerotinia sclerotiorum IFO 9395. J. Pharmacobiodyn. 10:478.
19. Williams, D. L., E. R. Sherwood, I. W. Browder, R. B. McNamee, E. L. Jones, and N. R. Di Luzio. 1988. Pre-clinical safety evaluation of soluble glucan. Int. J. Immunopharmacol. 10:405.
20. Tanabe, H., N. Imai, and K. Takechi. 1990. Studies on usefulness of postoperative adjuvant chemotherapy with lentinan in patients with gastrointestinal cancer. J. Jpn. Soc. Cancer Ther. 25:1657.
21. Arinaga, S., N. Karimine, K. Takamuku, S. Nanbara, M. Nagamatsu, H. Ueo, and T. Akiyoshi. 1992. Enhanced production of interleukin 1 and tumor necrosis factor by peripheral monocytes after lentinan administration in patients with gastric carcinoma. Int. J. Immunopharmacol. 14:43.
22. Kimura, Y., H. Tojima, S. Fukase, and K. Takeda. 1994. Clinical evaluation of sizofilan as assistant immunotherapy in treatment of head and neck cancer. Acta Otolaryngol. (Stockh.) 511(Suppl.):192.
23. Nakano, T., K. Oka, K. Hanba, and S. Monta. 1996. Intratumoral administration of sizofiran activates Langerhans cell and T-cell infiltration in cervical cancer. Clin. Immunol. Immunopathol. 79:79.
24. Ceriani, R. L., J. A. Peterson, E. W. Blank, C. M. Chan, and R. Cailleau. 1992. Development and characterization of breast carcinoma cell lines as in vitro and in vivo models for breast cancer diagnosis and therapy. In Vitro Cell. Dev. Biol. 28A:397.
25. Thornton, B. P., V. Vetvicka, and G. D. Ross. 1994. Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes. J. Immunol. 152:1727.
26. Breard, J., E. L. Reinherz, P. C. Kung, G. Goldstein, and S. F. Schlossman. 1980. A monoclonal antibody reactive with human peripheral blood monocytes. J. Immunol. 124:1943.
27. Eddy, A., S. L. Newman, F. Cosio, T. LeBien, and A. Michael. 1984. The distribution of the CR3 receptor on human cells and tissue as revealed by a monoclonal antibody. Clin. Immunol. Immunopathol. 31:371.
28. 3) has lectin-like properties analogous to bovine conglutinin and functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b. J. Immunol. 134:3307.
29. 3. J. Clin. Invent. 82:640.
30. Bauume, D. M., M. J. Robertson, H. Levine, T. J. Manley, P. W. Schow, and J. Ritz. 1992. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. Eur. J. Immunol. 22:1.
31. Shevach, E. M. 1992. Immunofluorescence and cell sorting. In Current Protocols in Immunology. J. E. Colligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober, eds. John Wiley and Sons, New York, p. 5.0.1.
32. Lambris, J. D., N. J. Dobson, and G. D. Ross. 1980. Release of endogenous C3b inactivator from lymphocytes in response to triggering membrane receptors for β1H globulin. J. Exp. Med. 152:1625.
33. Winchester, R. J., and G. D. Ross. 1986. Methods for enumerating cell populations by surface markers using conventional microscopy. In Manual of Clinical Laboratory Immunology, 3rd Ed. N. R. Rose, H. Friedman, and J. L. Fahey, eds. American Society for Microbiology, Washington, D.C., p. 212.
34. Peterson, J. A., J. R. Couto, M. R. Taylor, and R. L. Ceriani. 1995. Selection of tumor-specific epitopes on target antigens for radioimmunotherapy of breast cancer. Cancer Res. 55:5847:S.
35. Peterson, J. A., and R. L. Ceriani. 1994. Breast mucin and associated antigens in diagnosis and therapy. Adv. Exp. Med. Biol. 353:1.
36. Bayer, E. A., and M. Wilchek. 1980. The use of the avidin-biotin complex as a tool in molecular biology. Methods Biochem. Anal. 26:1.
37. Timonen, T., C. W. Reynolds, J. R. Ortaldo, and R. B. Herberman. 1982. Isolation of human and rat natural killer cells. J. Immunol. Methods 51:269.
38. Theofilopoulos, A. N., and L. H. Perrin. 1977. Lysis of human cultured lymphoblastoid cells by cell-induced activation of the properdin pathway. Science 195: 878.
39. Schreiber, R. D., M. K. Pangburn, R. G. Medicus, and H. J. Müller-Eberhard. 1980. Raji cell injury and subsequent lysis by the purified cytolytic alternative pathway of human complement. Clin. Immunol. Immunopathol. 15:384.
40. Mold, C., G. R. Nemerow, B. M. Bradt, and N. R. Cooper. 1988. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells. J. Immunol. 140:1923.
41. Caudwell, V., F. Porteu, A. Calender, M. K. Pangburn, and L. Halbwachs-Mecarelli. 1990. Complement alternative pathway activation and control on membranes of human lymphoid B cell lines. Eur. J. Immunol. 20:2643.
42. Morton, D. L., R. A. Malmgren, E. C. Holme, and A. S. Ketcham. 1968. Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 64:233.
43. Okada, H., and T. Baba. 1974. Rosette formation of human erythrocytes on cultured cells of tumour origin and activation of complement by cell membrane. Nature 248:521.
44. McCoy, J. P., D. E. Hofheinz, A. B. Ng, S. Nordqvist, and H. G. Haines. 1979. Tumor-bound immunoglobulin in human gynecologic cancers. J. Natl. Cancer Inst. 63:279.
45. Mariani-Costantini, R., R. Muraro, F. Ficari, C. Valli, R. Bei, F. Tonelli, F. Caramia, and L. Frati. 1991. Immunohistochemical evidence of immune responses to tumor-associated antigens in lymph nodes of colon carcinoma patients. Cancer 67:2880.
46. Sorokine, I., K. Ben-Mahrez, A. Bracone, D. Thierry, S. Ishii, F. Imamoto, and M. Kohiyama. 1991. Presence of circulating anti-c-myb oncogene product antibodies in human sera. Int. J. Cancer 47:665.
47. Irie, K., R. F. Irie, and D. L. Morton. 1975. Detection of antibody and complement completed in vivo on membranes of human cancer cells by mixed hemadsorption techniques. Cancer Res. 35:1244.
48. Schlom, J., D. Wunderlich, and Y. Teramoto. 1980. Generation of human monoclonal antibodies reactive with human mammary carcinoma cells. Proc. Natl. Acad. Sci. USA 77:6841.
49. Pfreundschuh, M., M. Rohrich, W. Piotrowski, P. Berlit, and H. Penzholz. 1982. Natural antibodies to cell-surface antigens of human astrocytoma. Int. J. Cancer 29:517.
50. Cote, R. J., D. M. Morrissey, A. N. Houghton, E. J. Beattie, Jr., H. F. Oettgen, and L. J. Old. 1983. Generation of human monoclonal antibodies reactive with cellular antigens. Proc. Natl. Acad. Sci. USA 80:2026.
51. Cheung, N.-K. V., E. I. Walter, W. H. Smith-Mensah, W. D. Ratnoff, M. L. Tykocinski, and M. E. Medof. 1988. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J. Clin. Invest. 81: 1122.
52. Hakulinen, J., and S. Meri. 1994. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab. Invest. 71:820.
53. Mäenpää, A., S. Junnikkala, J. Hakulinen, T. Timonen, and S. Meri. 1996. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am. J. Pathol. 148:1139.
54. Reiter, Y., A. Ciobotariu, and Z. Fishelson. 1992. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. Eur. J. Immunol. 22:1207.
55. Jean, D., M. Bar-Eli, S. Y. Huang, K. P. Xie, F. Rodrigues-Lima, J. Hermann, and R. Frade. 1996. A cysteine proteinase, which cleaves human C3, the third component of complement, is involved in tumorigenicity and metastasis of human melanoma. Cancer Res. 56:254.
56. Perlmann, P., H. Perlmann, and H. J. Müller-Eberhard. 1975. Cytolytic lymphocytic cells with complement receptor in human blood: induction of cytolysis by IgG antibody but not by target cell-bound C3. J. Exp. Med. 141:287.
57. Klein, E., L. Di Renzo, and E. Yefenof. 1990. Contribution of CR3, CD11b/ CD18 to cytolysis by human NK cells. Mol. Immunol. 27:1343.
58. Lipari, M., L. Di Renzo, A. Zicari, S. Serarcangeli, H. P. Huemer, C. Larcher, M. P. Dierich, and G. Pontieri. 1991. Macrophage tumor cell interaction is enhanced by C3 fragments. Immunobiology 183:363.
59. Perlmann, H., P. Perlmann, R. D. Schreiber, and H. J. Müller-Eberhard. 1981. Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors: enhancement of antibody-mediated cellular cytotoxicity. J. Exp. Med. 153:1592.
60. Wåhlin, B., H. Perlmann, P. Perlmann, R. D. Schreiber, and H. J. Müller-Eberhard. 1983. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments. J. Immunol. 130:2831.
61. Baxevanis, C. N., G. J. Reclos, A. D. Gritzapis, G. V. Z. Dedousis, I. Missitzis, and M. Papamichail. 1993. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer 72:491.
62. Litwin, V., J. Gumperz, P. Parham, J. H. Phillips, and L. L. Lanier. 1994. NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J. Exp. Med. 180:537.
63. Moretta, A., M. Vitale, S. Sivori, C. Bottino, L. Morelli, R. Augugliaro, M. Barbaresi, D. Pende, E. Ciccone, M. Lopez-Botet, and L. Moretta. 1994. Human natural killer cell receptors for HLA-class I molecules: evidence that the Kp43 (CD94) molecule functions as receptor for HLA-B alleles. J. Exp. Med. 180:545.
64. Moretta, A., C. Bottino, M. Vitale, D. Pende, R. Biassoni, M. C. Mingan, and L. Moretta. 1996. Receptors for HLA class-I molecules in human natural killer cells. Annu. Rev. Immunol. 14:619.
65. Ross, G. D., and V. Vetvicka. 1996. Targeting of murine macrophages and NK Cells to mammary carcinomas via naturally occurring tumor cell-bound iC3b and β-glucan-primed CR3 (CD11b/CD18). J. Leukocyte Biol. 59(Suppl.):24 (Abstr.).
66. Di Luzio, N. R. 1985. Update on the immunomodulating activities of glucans. Springer Semin. Immunopathol. 8:387.
67. Taguchi, T. 1987. Clinical efficacy of lentinan on patients with stomach cancer: end point results of a four-year follow-up survey. Cancer Detect. Prev. 1(Suppl): 333.
68. Chihara, G. 1990. Lentinan and its related polysaccharides as host defense potentiators: their application to infectious diseases and cancer. In Immunotherapeutic Prospects of Infectious Diseases. K. N. Masihi and W. Lange, eds. Springer-Verlag, Berlin, p. 9.
69. Fukushima, M. 1996. Adjuvant therapy of gastric cancer: the Japanese experience. Semin. Oncol. 23:369.